Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 2, 2012, Pages 221-225

  Mahatthanatrakul, W ^a   Sriwiriyajan, S ^a   Ridtitid, W ^b   Boonleang, J ^a   Wongnawa, M ^a   Rujimamahasan, N ^a   Pipatrattanaseree, W ^c  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b WALAILAK UNIVERSITY   (Thailand)

^c Drug Section   (Thailand)

Author keywords

9 hydroxyrisperidone; Drug drug interaction; Ketoconazole; Pharmacokinetics; Risperidone

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; PALIPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; EXTRAPYRAMIDAL SYNDROME; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; HALF-LIFE; HUMANS; ISOXAZOLES; KETOCONAZOLE; MALE; PYRIMIDINES; RISPERIDONE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84857992380     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01271.x     Document Type: Article

References (20)

1. 2 dopamine receptor occupancy by risperidone in the living human brain. Journal of Psychopharmacology, 1993;110:265-272.
2. Marder SR, Davis JM, Chouinard G The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American Trials. Journal of Clinical Psychiatry, 1997;58:538-546. (Pubitemid 28100274)
3. Chouinard G, Arnott W Clinical review of risperidone. Canadian Journal of Psychiatry, 1993;38(Suppl. 3), S89-S95.
4. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S Risperidone versus haloperidol in the treatment of chronic schizophrenia inpatients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica, 1992;85:295-305.
5. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E The pharmacokinetics of risperidone in humans: a summary. Clinical Psychiatry, 1994;55:13-17. (Pubitemid 24179364)
6. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J Absorption, metabolism and excretion of risperidone in humans. Drug Metabolism &Disposition, 1993;21:1134-1141. (Pubitemid 23348354)
7. Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunbhanich M Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. Journal of Clinical Pharmacy and Therapeutics, 2007;32:161-167. (Pubitemid 46449707)
8. Huang ML, Van PA, Woestenborghs R et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Journal of Clinical Pharmacology and Therapeutics, 1993;54:257-268. (Pubitemid 23294526)
9. Leysen JE, Gommeren W, Eens A, De Chaffoy de Courcelles D, Stoof JC, Janssen PAJ Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics, 1988;247:661-670.
10. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as in vivo probe: effect of ketoconazole. Journal of Clinical Pharmacology and Therapeutics, 1999;66:461-471.
11. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raunsri N, Sunbhanich M Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. Journal of Clinical Pharmacy and Therapeutics, 2005;30:285-290. (Pubitemid 41603053)
12. Remmerie BM, Sips LL, de Vries R, de Jong J, Schothuis AM, Hooijschuur EW, Van de Merbel NC Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, 2003;783:461-472 (doi: 10.1016/S1570-0232(02)00715-8).
13. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine (2001) Guidance for industry: bioanalytical method validation. Washington, DC: US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine.
14. Fang J, Bourin M, Baker GB Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn- Schmiedeberg's Archives Pharmacology, 1999;359:147-151. (Pubitemid 29142884)
15. Boulton DW, DeVane CL, Liston HL, Markowitz JS In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sciences, 2002;71:163-169. (Pubitemid 34595435)
16. Ejsing TB, Pedersen AD, Linnet K P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knockout mice and in drug-drug interaction experiments. Human Psychopharmacology Clinical and Experimental, 2005;20:493-500. (Pubitemid 41489461)
17. Cousein E, Barthelemy C, Poullain S et al. P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro CaCo-2/TC7 model and in vivo model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007;31:878-886. (Pubitemid 46671480)
18. Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Journal of Clinical Pharmacology and Therapeutics, 2005;78:520-528. (Pubitemid 41698906)
19. Vermeir M, Naessens I, Remmerie B et al. Absorption, metabolism, and excretion of paliperidone, a new momoaminergic antagonist in human. Drug Metabolism &Disposition, 2008;36:769-779. (Pubitemid 351468385)
20. Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG Different enantioselective 9-Hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metabolism & Disposition, 2001;29:1263-1268. (Pubitemid 32896574)